Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin

Asia-Pacific Journal of Clinical Oncology

Volumn 3, Issue 2, 2007, Pages 66-78

  Armour, Alison ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

EGFR; Gefitinib; ISEL; Mutation; NSCLC

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; KI 67 ANTIGEN; METHIONINE; NAVELBINE; PACLITAXEL; PLACEBO; PROTEIN KINASE B; RANTES; STAT PROTEIN; THREONINE;

ADJUVANT THERAPY; ADVANCED CANCER; AMINO ACID SUBSTITUTION; ASIA; ASIAN; BLOOD TOXICITY; BRAIN METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; EMBASE; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MEDLINE; META ANALYSIS; MUTATION RATE; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN DISEASE; SURVIVAL TIME; SYSTEMATIC REVIEW; TUMOR REGRESSION;

EID: 34249979517     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2007.00090.x     Document Type: Review

References (103)

1. Parkin M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (IRESSA Survival Evaluation in Lung cancer). Lancet 2005; 366: 1527-37.
3. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46.
4. Nakagawa K, Tamura T, Negoro S et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumours. Ann Oncol 2003; 14: 922-30.
5. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Cur Med Res Opin 2006; 22: 561-73.
6. Thomas SK, Fossella FV, Liu D et al. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 2006; 7: 326-31.
7. Bell DW, Lynch TJ, Haserlat SM et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23: 8081-92.
8. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
9. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003; 290: 2149-58.
10. Nishiwaki Y, Yano S, Tamura T et al. [Subset analysis of data in Japanese patients with NSCLC from IDEAL 1 study on gefitinib]. Gan To Kagaku Ryoho 2004; 31: 567-73. (In Japanese)
11. Fujiwara Y, Kiura K, Toyooka S et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2006; 52: 99-103.
12. Goto K, Kim E, Kubota K et al. Association of multiple pulmonary metastases with response to gefitinib in patients with non-small cell lung cancer. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings; 22 (14S): Abs 7098 [Abstract].
13. Hotta K, Kiura K, Ueoka H et al. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 46: 255-61.
14. Hotta K, Matsuo K, Ueoka H et al. Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Ann Oncol 2005; 16: 1817-23.
15. Kakiuchi S, Daigo Y, Ishikawa N et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004; 13: 3029-43.
16. Kaneda H, Tamura K, Kurata T, Uejima H, Nakagawa K, Fukuoka M. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 46: 247-54.
17. Katakami N, Okazaki M, Kinose D et al. A retrospective analysis of the outcome of patients (pts) in advanced recurrent adenocarcinoma of the lung who have received gefitinib after treatment of platinum-based regimen. Proc Am Soc Clin Oncol 2003; 22: 2679 [Abstract].
18. Kim YH, Ishii G, Goto K et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004; 10: 7311-17.
19. Kinoshita A, Fukuda M, Nagashima S et al. Pulmonary damage during gefitinib monotherapy in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22: 2809 [Abstract].
20. Kishi K, Homma S, Miyamoto A, Sakamoto S, Motoi N, Yoshimura K. Factors predicting the efficacy of gefitinib in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings; 23 (16S): Abs 7095 [Abstract].
21. Matsuura K, Kudoh S, Mitsuoka S et al. Evaluating a prognostic factor in advanced adenocarcinoma of the lung who have treated with gefitinib. J Clin Oncol, 2004, ASCO Annual Meeting Proceedings; 22 (14S): Abs 7334 [Abstract].
22. Nakagawa M, Teramukai S, Tada H et al. Hypoalbuminemia as a risk factor of interstitial lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC): A JMTO study. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings; 23 (16S): Abs 7190 [Abstract].
23. Takano T, Ohe Y, Kusumoto M et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004; 45: 93-104.
24. Takano T, Ohe Y, Sakamoto H et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829-37.
25. Guan Z, Zhang L, Li L et al. A Chinese, multicenter, phase II trial of gefitinib (IRESSA) in patients with non-small-cell lung cancer who had failed previous chemotherapy. Poster 2264 presented at the 11th WCLC, Barcelona, Spain, 3-6 July 2005.
26. Jiang G, Hong X, Fan M et al. [Iressa for refractory non-small-cell lung cancer: A preliminary report]. Chin J Lung Cancer 2004; 7: 305-8. (In Chinese)
27. Li W, Li L, Li J, Zhou Q. [Iressa for the non-small lung cancer patients who failed prior chemotherapy and radiotherapy]. Chin J Lung Cancer 2004; 7: 321-4. (In Chinese)
28. Mu X-L, Li L-Y, Zhang X-T, Wang S-L, Wang M-Z. Evaluation of safety and efficacy of gefitinib ('IRESSA', ZD1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: Experience from a compassionate-use programme. BMC Cancer 2004; 4: 51-9.
29. Wang MZ, Li LY, Wang SL, Zhang XT, Zhong W, Zhang L. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl) 2006; 119: 63-8.
30. Wu YL, Yang X, Yang J-J, Huang Y-J, Chen G, Gu L-J. ZD1839 for the treatment of heavily pretreated non-small cell lung cancer. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings; 22 (14S): Abs 7341 [Abstract].
31. Zhang XT, Li LY, Chang X-Y et al. Efficacy and correlation with predictive markers of gefitinib in pretreated Chinese patients with advanced NSCLC. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings; 23 (16S): Abs 7240 [Abstract].
32. Han SW, Hwang PG, Chung DH et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa ®, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005; 113: 109-15.
33. Kim KS, Jeong JY, Kim YC et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005; 11: 2244-51.
34. Lee SW, Kim DR, Lee SD et al. [The efficacy of ZD1839 (Iressa) in patients with advanced non-small-cell lung cancer which has progressed after previous chemotherapy]. Tuberc Respir Dis 2004; 57: 160-7. (In Korean)
35. Park J, Park BB, Kim JY et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004; 10: 4383-8.
36. Chang G-C, Chen K-C, Yang T-Y et al. Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Invest New Drugs 2005; 23: 73-7.
37. Chiu C-H, Tsai C-M, Chen Y-M, Chiang S-C, Liou J-L, Perng R-P. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005; 47: 129-38.
38. Suzuki R, Hasegawa Y, Baba K et al. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br J Cancer 2006; 94: 1599-603.
39. Hashizume T, Ogura T, Kozawa S et al. [Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer]. Gan To Kagaku Ryoho 2006; 33: 467-70. (In Japanese)
40. Kasahara K, Kimura H, Yoshimoto A et al. A phase II study of gefitinib monotherapy for chemotherapy-naive patients with non-small cell lung cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings; 23 (16S): abs 7074 [Abstract].
41. Niho S, Kubota K, Goto K et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 2006 24: 64-9.
42. Lee DH, Han JY, Lee HG et al. A phase II study of gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in lifetime non-smokers. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 23 (16S): Abs 7072 [Abstract].
43. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA™) monotherapy. Clinical experience in non-small-cell lung cancer. Drug Saf 2004; 27: 1081-92.
44. Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003; 22: 179-81.
45. Inoue A, Saijo Y, Maemondo M et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-9.
46. Okamoto I, Suga M. Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer? Intern Med 2003; 42: 926-7.
47. Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs 2003; 14: 665-8.
48. Sumpter K, Congleton J, Harper-Wynne C, O'Brien M. Severe acute interstitial pneumonia and gefitinib. Lung Cancer 2004; 43: 367-8 [Letter].
49. Bhatia S, Hanna N, Ansari R et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 2002; 38: 73-7.
50. Chen Y-M, Perng R-P, Yang K-Y et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer. Chest 2000; 117: 1583-9.
51. Rebattu P, Quantin X, Ardiet C et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 2001; 33: 277-87.
52. Thomas AL, Cox G, Sharma RA et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: Report of a phase I/II dose-escalating study. Eur J Cancer 2000; 36: 2329-34.
53. Willner J, Schmidt M, Kirschner J et al. Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol ®) and 3D-conformal radiotherapy of stage III inoperable non small cell lung cancer. Results of a dose escalation study. Lung Cancer 2001; 32: 163-71.
54. Yoshida S. The results of gefitinib prospective investigation. Med Drug J 2005; 41: 772-89.
55. Ando M, Okamoto I, Yamamoto N et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006; 24: 2549-56.
56. Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 1986; 149: 9-14.
57. Rusch V, Baselga J, Cordon-Cardo C et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 2379-85.
58. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-50.
59. Ranson M. ZD1839 (Iressa™): For more than just non-small cell lung cancer. Oncologist 2002; 7 (Suppl. 4): 16-24.
60. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5034-42.
61. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy. Eur J Cancer 2006; 42: 17-23.
62. Han S-W, Kim T-Y, Hwang PG et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23: 2493-501.
63. Huang SF, Liu HP, Li LH et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10: 8195-203.
64. Kondo M, Yokoyama T, Fukui T et al. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 2005; 50: 385-91.
65. Koyama N. Examination of the antitumour effects of gefitinib in patients with non-small cell lung cancer and EGFR mutations. Lung Cancer 2004; 44: 355 [Abstract].
66. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
67. Mu XL, Li LY, Zhang XT et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 4289-94.
68. Rosell R, Ichinose Y, Taron M et al. Non-small-cell lung cancer (NSCLC) tumors from gefitinib-responsive patients (pts) harbor EGFR kinase domain mutations. Ann Oncol 2004; 15 (Suppl. 3): 629O [Abstract].
69. Tokumo M, Toyooka S, Kiura K et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005; 11: 1167-73.
70. Wu Y, Zhong W et al. EGFR mutations and the correlation with gefitinib therapy in Chinese NSCLC - A systematic review based on individual patient data from 5 medical centers in China. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): Abs 7187 [Abstract].
71. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351: 2883.
72. Sasaki H, Shimizu S, Endo K et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006; 118: 180-4.
73. Tomizawa Y, Iijima H, Sunaga N et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11: 6816-22.
74. Han SW, Kim TY, Jeon YK et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 2006a; 12: 2538-44.
75. Kimura H, Fujiwara Y, Sone T et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006; 97: 642-8.
76. Kimura H, Kasahara K, Kawaishi M et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006; 12: 3915-21.
77. Kasahara K, Sone T, Kimura H et al. Corrrelation between epidermal growth factor gene status and clinical outcome of gefitinib in Japanese patients with non-small cell lung cancer. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): Abs 7192 [Abstract].
78. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-20.
79. Morikawa N, Inoue A, Suzuki T et al. Prospective analysis of the epidermal growth factor receptor gene mutations in non-small cell lung cancer in Japan. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): Abs 7077 [Abstract].
80. Sasaki H, Endo K, Mizuno K et al. EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. Lung Cancer 2006; 51: 135-6.
81. Shih JY, Gow CH, Yu CJ et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006; 118: 963-9.
82. Takano T, Ohe Y, Furuta K et al. EGFR mutations detected by high-resolution melting analysis (HRMA) as a predictor of response and survival in non-small cell lung cancer (NSCLC) patients treated with gefitinib. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): abs 7075 [Abstract].
83. Sutani A et al. Phase II study of gefitinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNA-LA PCR clamp. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): Abs 7076 [Abstract].
84. Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24: 3340-6.
85. Sunaga N, Yanagitani K, Kaira K et al. Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): abs 7183 [Abstract].
86. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92.
87. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: E73.
88. Mitsudomi T, Kosaka T, Endoh H et al. Mutational analysis of the EGFR gene in lung cancer with acquired resistance to gefitinib. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): Abs 7074 [Abstract].
89. Pao W, Balak MN, Riely GJ et al. Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): Abs 7078 [Abstract].
90. Kakiuchi S, Yano S, Ogino H, Nakamura Y, Tsuruo T, Sone S. Quantitative RT-PCR analysing expression of gefitinib resistance related genes predicts clinical outcome of non-small cell lung cancer patients treated with gefitinib. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): Abs 7181 [Abstract].
91. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PloS Med 2005; 2: E17.
92. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-7.
93. Meert AP, Martin B, Delmotte P et al. The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis. Eur Respir J 2002; 20: 975-81.
94. Han SW, Kim TY, Lee KW et al. EGFR mutation and intron 1 CA repeat polymorphism as predictive markers of gefitinib responsiveness in non-small cell lung cancer (NSCLC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): Abs 7173 [Abstract].
95. Nakamura Y, Sano K, Fukuda M et al. Pharmacokinetics of gefitinib predicts the antitumor activity for advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): abs 2009 [Abstract].
96. Nishio M, Taguchi F, Ohyanagi F et al. Correlation between gefitinib efficacy and HER family expression in recurrent non-small-cell lung cancer (NSCLC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings; 22 (14S): Abs 3091 [Abstract].
97. Yamaguchi K, Kanazawa S, Muramatsu Y, Kinoshita Y, Nomura S. Elevation of plasma RANTES levels and prognosis in patients treated with gefitinib. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings; 23 (16S): abs 3215 [Abstract].
98. Tsao M-S, Sakurada A, Cutz J-C et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44.
99. Cappuzzo F, Toschi L, Trisolini R et al. Clinical and biological effects of gefitinib in EGFR FISH positive/phospho-akt positive or never smoker non-small cell lung cancer (NSCLC): Preliminary results of the ONCOBELL trial. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): Abs 7023 [Abstract].
100. Crinò L, Zatloukal P, Reck M et al. First-line gefitinib (IRESSA) versus vinorelbine (INVITE): A randomized Phase II study in elderly patients with advanced non-small-cell lung cancer. Abstract presented at Targeted Anticancer Therapies (TAT) 2007 Conference, Amsterdam, The Netherlands, 8-10 March 2007; abs 0404. Ann Oncol Suppl, 2007, in press.
101. Varella-Garcia M, Mitsudomi T, Yatabe Y et al. EGFR genomic gain in Japanese non-small cell lung cancer patients treated with gefitinib. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings; 24 (18S): Abs 7164 [Abstract].
102. Miller VA, Kris MG, Shah N et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103-9.
103. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.